Alzheimer’s Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of alzheimer’s disease comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of alzheimer’s disease for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s alzheimer’s disease forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of alzheimer’s disease and the number of new diagnoses of alzheimer’s disease?
- Of all people diagnosed with alzheimer’s disease, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of alzheimer’s disease over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following alzheimer’s disease subpopulations:
- Asymptomatic AD prevalent cases.
- Total MCI due to AD prevalent cases.
- Asymptomatic AD incident cases.
- Total MCI due to AD incident cases.
- Total AD incident cases.
- Diagnosed AD prevalent cases.
- Diagnosed MCI due to AD prevalent cases.
- Diagnosed AD prevalent cases by symptom status (agitation, depression, hallucinations).
- Diagnosed AD prevalent cases by severity
- Diagnosed drug-treated AD prevalent cases.
- Diagnosed drug-treated mild AD prevalent cases.
- Diagnosed drug-treated moderate AD prevalent cases.
- Diagnosed drug-treated severe AD prevalent cases.
… and many more (details available on request).
Note: Coverage may vary by country.
